« Top Headlines » Open DEMAT Account in 24 hrs  How to Change Current Period in Tally Prime Step-by-Step Guide for Users  Global Payroll Management with Tally Prime: How International Businesses Use It Beyond India  How to Manage B2B HSN Codes in Tally Prime: A Complete Guide for Businesses  How to Check Business Revenue in Tally Prime: A Complete Step-by-Step Guide  MSME Payment Rule in Tally Prime: Understanding the Law and Its Impact on Businesses in 2025 The MSME (Micro, Small and Medium Enterprises) Payment Rule is a legal framework introduced under th  Multipurpose Empanelment Form (MEF) 2025 26 Meaning, Purpose, and How to Manage It in Tally Prime  GST Appellate Tribunal (GSTAT) Structure, Powers, and Its Relevance in Tally Prime Implementation  How Tally Prime Supports the Real Estate & Construction Industry in India  Comparison Between Tally Prime 6.1 and Tally Prime 6.2  How Tally Prime Renewal Helps Save My Data  Where to Buy Tally Prime 7.0 at the Best Rates Possible «  Telecom industry for tax holiday... HC notice to finmin over non-CA tax preparers... » Cabinet to look into amendment November, 21st 2006 In a move that will boost the pharmaceutical sector, the Cabinet Committee on World Trade Organisation is expected to take up a proposal for amending the compulsory license clause in the Trade-Related Intellectual Property Rights (TRIPS) agreement.    Once this decision is taken, the Centre will propose to WTO to waive off the obligation under Article 31(f) and Article 31(h) of the TRIPS agreement, so that it can directly export pharma products to countries having insufficient or no manufacturing capacity.    Under the current circumstances, a government has an exceptional provision of allowing a pharma company to produce the patented product or process without the consent of the patent owner in case of a medical emergency.    But if the article is relaxed for India, domestic companies will be able to export the products to other countries in case of national emergencies without the authorisation of the patent holder.    Article 31(h) of TRIPS specifies that the right holder shall be paid adequate remuneration in the circumstances of each case, taking into account the economic value of the authorisation benefit.